Sino Biopharmaceutical Gains FDA Approval for New Cancer Drug
Sino Biopharmaceutical (HK:1177) has released an update. Sino Biopharmaceutical has received approval from the U.S. FDA to commence Phase I ...
mskcc.org9d
How MSK Cares for a Young Woman Living With Stage 4 EGFR Lung Cancer
Learn how a young woman diagnosed with stage 4 non-small cell lung cancer had many treatment options because she came to MSK first.
BioWorld14d
NMPA clears Alpha’s oral EGFR-TKI for NSCLC with brain metastases
China’s drug regulator approved Alpha Biopharma Ltd.’s EGFR tyrosine kinase inhibitor (TKI), Zorifer (zorifertinib hydrochloride tablets; AZD-3759), as a first-line treatment for EGFR-mutated ...
Yahoo Finance29d
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
an orally bioavailable allosteric degrader of EGFR L858R for non-small cell lung cancer (NSCLC), in Greater China. “We are pleased to see CFT8919, our fourth small molecule degrader to enter the ...